Last $0.0001 USD
Change Today -0.0001 / -50.00%
Volume 900.0
TBET On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

tibet pharmaceuticals inc (TBET) Snapshot

Open
$0.0001
Previous Close
$0.0002
Day High
$0.0001
Day Low
$0.0001
52 Week High
01/15/14 - $0.01
52 Week Low
12/19/14 - $0.0001
Market Cap
1.5K
Average Volume 10 Days
8.8K
EPS TTM
$0.80
Shares Outstanding
14.8M
EX-Date
--
P/E TM
0.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for TIBET PHARMACEUTICALS INC (TBET)

Related News

No related news articles were found.

tibet pharmaceuticals inc (TBET) Related Businessweek News

No Related Businessweek News Found

tibet pharmaceuticals inc (TBET) Details

Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. The company, through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), develops products in China for promoting health in human respiratory, digestive, urinary, and reproductive systems. Its commercialized products include 25 Ingredients Mandrake Pill, which is used to regulate menses to treat endometritis, pelvic inflammations, and women’s anemia; 15 Ingredients Gentiana Pill to treat bronchitis, emphysema, asthma, and hoarseness; 28 Ingredients Pinang Pill for treating cold waist hip pain, pus hematuria, and testis swelling; 18 Ingredients Chebulic (Myrobalan) Frusemide Pill for the treatment of kidney problems, lumbar and kidney pain, frequent urination, turbid urine, diabetes, and spermatorrhea; and Pomegranate Nichirin Pill to treat indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emission. The company also develops Xuezang Guben pill indicated for the treatment of neurasthenia, insomnia, frequent urination, nocturnal emission, and women’s menopausal symptoms; Shengke I that is in Phase III clinical testing for treating type II diabetes; Shengke II, which is in Phase II clinical testing for treating impotence and premature ejaculation, prostrate disease, and memory loss; Jiuzan pill that is in Phase II clinical testing for the treatment of chronic gastroenteritis and peptic ulcers; and Antai pill, a pre-clinical stage product for treating hepatitis B. In addition, it focuses to commercialize Wupeng Pill for treating echimococosis, pandora tingling disease, diphtheria, anthrax, yellow water disease, and leprosy. The company was formerly known as Shangri-La Tibetan Pharmaceuticals, Inc. and changed its name to Tibet Pharmaceuticals Inc. in July 2010. Tibet Pharmaceuticals, Inc. is headquartered in Wanchai, Hong Kong.

190 Employees
Last Reported Date: 03/30/11

tibet pharmaceuticals inc (TBET) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TBET:US $0.00 USD -0.0001

TBET Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TBET.
View Industry Companies
 

Industry Analysis

TBET

Industry Average

Valuation TBET Industry Range
Price/Earnings 0.0x
Price/Sales 0.0x
Price/Book 0.0x
Price/Cash Flow 0.0x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TIBET PHARMACEUTICALS INC, please visit www.tibetpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.